Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 5/2019

01-09-2019 | Breast Cancer | Rapid Communication

Discrepancies of current recommendations in breast cancer follow-up: a systematic review

Authors: Anastasios Kyriazoglou, Flora Zagouri, Despina Fotiou, Constantinos Dimitrakakis, Spyros Marinopoulos, Roubini Zakopoulou, Maria Kaparelou, Anna Zygogianni, Meletios Athanasios Dimopoulos

Published in: Breast Cancer | Issue 5/2019

Login to get access

Abstract

Introduction

Management and optimal follow-up of early breast cancer survivors remain up to this day a challenge due to the lack of well-established guidelines. Multiple medical societies, organizations and working groups have provided recommendations for follow-up but there is no uniform, globally approved algorithm to guide clinical practice.

Methods

A systematic review was performed to identify and evaluate discrepancies between available guidelines for the follow-up of breast cancer survivors.

Results

Differences in the follow-up schedule, laboratory and imaging investigations were noted. In the clinical practice setting, the situation is complicated further by clinicians who often request unnecessary tests not currently incorporated in any of the existing guidelines.

Conclusions

Follow-up of patients with early breast cancer needs to become standardized and prospective clinical trials focusing on optimal follow-up are more than mandatory.
Literature
1.
Mitus JW, Blecharz P, Walasek T, Reinfuss M, Jakubowicz J, Kulpa J. Treatment of patients with distant metastases from phyllodes tumor of the breast. World J Surg. 2016;40:323–8.CrossRefPubMed
2.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Cancer Netw. 2017;15:433–51.CrossRef
3.
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30.CrossRefPubMed
4.
Grunfeld E, Dhesy-Thind S, Levine M, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ. 2005;172:1319–20.CrossRefPubMedPubMedCentral
5.
Thomssen C, Scharl A, Harbeck N. AGO recommendations for diagnosis and treatment of patients with primary and metastatic breast cancer. Update 2011. Breast Care (Basel). 2011;6:299–313.CrossRef
6.
Dewis R, Gribbin J. Breast cancer: diagnosis and treatment: an assessment of need. Cardiff: National Collaborating Centre for Cancer; 2009.
7.
Barnadas A, Algara M, Cordoba O, Casas A, Gonzalez M, Marzo M, et al. Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). Clin Transl Oncol. 2018;20:687–94.CrossRefPubMed
8.
Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611–35.CrossRef
9.
Australian Government NHaMRC. Clinical practice guideline for the management of early breast cancer, 2nd ed. Canberra: Australian Government NHaMRC; 2001.
10.
Larson KE, Grobmyer SR, Valente SA. Evaluation of recurrence patterns and survival in modern series of young women with breast cancer. Breast J. 2018;24(5):749–54.CrossRefPubMed
11.
Louie RJ, Tonneson JE, Gowarty M, Goodney PP, Barth RJ Jr, Rosenkranz KM. Complete blood counts, liver function tests, and chest X-rays as routine screening in early-stage breast cancer: value added or just cost? Breast Cancer Res Treat. 2015;154:99–103.CrossRefPubMed
12.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64.CrossRef
13.
De Placido S, De Angelis C, Giuliano M, Pizzi C, Ruocco R, Perrone V, et al. Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications. Br J Cancer. 2017;116:821–7.CrossRefPubMedPubMedCentral
14.
Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:961–5.CrossRefPubMed
15.
Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf). 2018;89(3):280–96.CrossRef
16.
Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA. Tumour Biol. 2018;40:1010428318776169.CrossRefPubMed
17.
Azim HA Jr, Davidson NE, Ruddy KJ. Challenges in treating premenopausal women with endocrine-sensitive breast cancer. Am Soc Clin Oncol Educ Book. 2016;35:23–32.CrossRefPubMed
18.
Schmidt ME, Wiskemann J, Steindorf K. Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual Life Res. 2018;27(8):2077–86.CrossRefPubMed
19.
Ghizzani A, Bruni S, Luisi S. The sex life of women surviving breast cancer. Gynecol Endocrinol. 2018;34(10):821–5.CrossRefPubMed
20.
Grunfeld E, Julian JA, Pond G, Maunsell E, Coyle D, Folkes A, et al. Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol. 2011;29:4755–62.CrossRefPubMed
21.
Berger O, Gronberg BH, Loge JH, Kaasa S, Sand K. Cancer patients’ knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study. BMC Cancer. 2018;18:381.CrossRefPubMedPubMedCentral
22.
Nippert I, Julian-Reynier C, Harris H, Evans G, van Asperen CJ, Tibben A, et al. Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners’ and breast surgeons’ current practice and preferred practice responsibilities. J Community Genet. 2014;5:69–79.CrossRefPubMed
23.
Mosconi P, Torri V, Cifani S, Ruggiata R, Meyerowitz BE, Apolone G, et al. The multi-centre assessment of quality of life: the Interdisciplinary Group for Cancer Care Evaluation (GIVIO) experience in Italy. Stat Med. 1998;17:577–85.CrossRefPubMed
24.
Williams ST, Sykes MC, Boon Lim P, Salciccioli JD. The 2015 advanced life support guidelines: a summary and evidence for the updates. Emerg Med J. 2016;33:357–60.CrossRefPubMed
25.
Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, et al. Intensive vs. standard post-operative surveillance in high-risk breast cancer patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. Jpn J Clin Oncol. 2015;45:983–6.CrossRefPubMed
26.
Metadata
Title
Discrepancies of current recommendations in breast cancer follow-up: a systematic review
Authors
Anastasios Kyriazoglou
Flora Zagouri
Despina Fotiou
Constantinos Dimitrakakis
Spyros Marinopoulos
Roubini Zakopoulou
Maria Kaparelou
Anna Zygogianni
Meletios Athanasios Dimopoulos
Publication date
01-09-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 5/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00963-6

Other articles of this Issue 5/2019

Breast Cancer 5/2019 Go to the issue

Original Article

Sentinel node mapping and ductal carcinoma in situ

Original Article

C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis

Original Article

Lateral thoracoaxillar dermal-fat flap for breast conserving surgery: the changes of the indication and long-term results

Correction

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

Correction

Correction to: Breast cancer cell motility is promoted by 14-3-3γ

Original Article

Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits